Conor Killmurray

Articles

Novel PARP inhibitor shows promise across solid tumors, including prostate cancer

April 12, 2022

Initial data from the phase 1/2a modular PETRA trial showed that the next-generation highly selective PARP1 inhibitor AZD5305 had comparable safety and promising clinical activity compared with first-generation PARP inhibitors.